Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive dahl salt-sensitive rat

Hypertension

Volumn 62, Issue 5, 2013, Pages 905-913

  Hye Khan, Md Abdul ^a   Neckář, Jan ^a,c   Manthati, Vijay ^b   Errabelli, Ramu ^b   Pavlov, Tengis S ^a   Staruschenko, Alexander ^a   Falck, John R ^b   Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

arachidonate epoxygenase; glomerular necrosis; hypertension; inflammation; oxidative stress

Indexed keywords

8 ISOPROSTANE; [(N (5 ((2ACETAMIDOBENZO[D]THIAZOL 4 YL)OXY) PENTYL) N ISOPROPYLHEPTANAMIDE)]; ALBUMIN; CCAAT ENHANCER BINDING PROTEIN; DRINKING WATER; EPOXYICOSATRIENOIC ACID; GLUCOSE REGULATORY PROTEIN 78; MALONALDEHYDE; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; NITRATE; NITRITE; UNCLASSIFIED DRUG; ICOSANOID; SALT INTAKE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD VESSEL REACTIVITY; CELL INFILTRATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; KIDNEY INJURY; MACROPHAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REDUCTION; RENAL PROTECTION; SALT INTAKE; UMBILICAL VEIN ENDOTHELIAL CELL; URINALYSIS; URINARY EXCRETION; ANIMAL; BLOOD PRESSURE; COMPLICATION; DAHL RAT; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; EICOSANOIDS; ENDOPLASMIC RETICULUM STRESS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; INFLAMMATION; KIDNEY; KIDNEY DISEASES; OXIDATIVE STRESS; RATS; RATS, INBRED DAHL; SODIUM CHLORIDE, DIETARY;

EID: 84886393761     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01949     Document Type: Article

References (50)

1. Kanbay M, Chen Y, Solak Y, Sanders PW. Mechanisms and consequences of salt sensitivity and dietary salt intake. Curr Opin Nephrol Hypertens. 2011;20:37-43.
2. Weinberger MH. Pathogenesis of salt sensitivity of blood pressure. Curr Hypertens Rep. 2006;8:166-170.
3. Weinberger MH. Sodium and blood pressure 2003. Curr Opin Cardiol. 2004;19:353-356.
4. Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res. 2010;33:975-980.
5. Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens. 2008;26:381-391.
6. Franco M, Sanchez-Lozada LG, Bautista R, Johnson RJ, Rodriguez- Iturbe B. Pathophysiology of salt-sensitive hypertension: a new scope of an old problem. Blood Purif. 2008;26:45-48.
7. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2:582-593.
8. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8:794-805.
9. Imig JD. Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol. 2010;56:329-335.
10. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012;92:101-130.
11. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005;46:975-981.
12. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009;297:F740-F748.
13. Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond). 2009;116:61-70.
14. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin- induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol. 2011;301:R1307-R1317.
15. Imig JD, Falck JR. Compositions and methods for the treatment of renal and cardiovascular disease. US Patent 7,550,617. 2009.
16. Falck JR, Kodela R, Manne R, Atcha KR, Puli N, Dubasi N, Manthati VL, Capdevila JH, Yi XY, Goldman DH, Morisseau C, Hammock BD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem. 2009;52:5069-5075.
17. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol. 2005;45:311-333.
18. Batchu SN, Lee SB, Qadhi RS, Chaudhary KR, El-Sikhry H, Kodela R, Falck JR, Seubert JM. Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br J Pharmacol. 2011;162:897-907.
19. Wadei HM, Textor SC. The role of the kidney in regulating arterial blood pressure. Nat Rev Nephrol. 2012;8:602-609.
20. Meng S, Cason GW, Gannon AW, Racusen LC, Manning RD Jr. Oxidative stress in Dahl salt-sensitive hypertension. Hypertension. 2003;41:1346-1352.
21. Imig JD, Campbell WB, Falck JR. Epoxyeicosatrienoic acid analogs and methods of making and using the same. International Patent Application PCT/US2012/032090.
22. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002;90:1028-1036.
23. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB. 14,15-epoxyeicosa- 5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension. 2003;42:555-561.
24. Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR. Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front Physiol. 2010;1:157.
25. Hye Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 2013;27:2946-2956.
26. Nagasawa T, Hye Khan MA, Imig JD. Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol. 2012;39:454-461.
27. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 2007;82:50-59.
28. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol. 2008;294:H2838-H2844.
29. Tian N, Thrasher KD, Gundy PD, Hughson MD, Manning RD Jr. Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Hypertension. 2005;45:934-939.
30. Tian N, Gu JW, Jordan S, Rose RA, Hughson MD, Manning RD Jr. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol. 2007;292:H1018-H1025.
31. Campese VM. Salt sensitivity in hypertension. Hypertension. 1994;23:531-550.
32. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA. 1996;275:1581-1589.
33. Shehata MF. Genetic and dietary salt contributors to insulin resistance in Dahl salt-sensitive (S) rats. Cardiovasc Diabetol. 2008;7:19.
34. Marino JP Jr. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr Top Med Chem. 2009;9:452-463.
35. Carroll MA. Role of the adenosine(2A) receptor-epoxyeicosatrienoic acid pathway in the development of salt-sensitive hypertension. Prostaglandins Other Lipid Mediat. 2012;98:39-47.
36. Pidkovka N, Rao R, Mei S, Gong Y, Harris RC, Wang WH, Capdevila JH. Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated phosphorylation. J Biol Chem. 2013;288:5223-5231.
37. Sun P, Antoun J, Lin DH, Yue P, Gotlinger KH, Capdevila J, Wang WH. Cyp2c44 epoxygenase is essential for preventing the renal sodium absorption during increasing dietary potassium intake. Hypertension. 2012;59:339-347.
38. Wei Y, Lin DH, Kemp R, Yaddanapudi GS, Nasjletti A, Falck JR, Wang WH. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol. 2004;124:719-727.
39. Manning RD Jr, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol. 2005;25:311-317.
40. Swei A, Lacy F, DeLano FA, Schmid-Schönbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension. 1997;30:1628-1633.
41. Swei A, Lacy F, Delano FA, Parks DA, Schmid-Schönbein GW. A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation. 1999;6:179-187.
42. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation. 1997;96:2407-2413.
43. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295:F53-F59.
44. Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003;14:2775-2782.
45. Liu L, Chen C, Gong W, Li Y, Edin ML, Zeldin DC, Wang DW. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther. 2011;339:451-463.
46. Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling. J Pharmacol Exp Ther. 2012;341:725-734.
47. Tian N, Moore RS, Braddy S, Rose RA, Gu JW, Hughson MD, Manning RD Jr. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol. 2007;293:H3388-H3395.
48. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension. 2006;48:149-156.
49. Kolattukudy PE, Niu J. Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway. Circ Res. 2012;110:174-189.
50. Kassan M, Galán M, Partyka M, Saifudeen Z, Henrion D, Trebak M, Matrougui K. Endoplasmic reticulum stress is involved in cardiac damage and vascular endothelial dysfunction in hypertensive mice. Arterioscler Thromb Vasc Biol. 2012;32:1652-1661.